Lack of association between joint hyperlaxity and, I: panic disorder, and II: reactivity to carbon dioxide in healthy volunteers

2001 ◽  
Vol 16 (2) ◽  
pp. 189-192 ◽  
Author(s):  
Jonathan Benjamin ◽  
Itzhak Z Ben-Zion ◽  
Pinhas Dannon ◽  
Shaul Schreiber ◽  
Gal Meiri ◽  
...  
Keyword(s):  
Carbon Dioxide ◽  
Panic Disorder ◽  
Healthy Volunteers

scholarly journals Respiratory panic disorder subtype and sensitivity to the carbon dioxide challenge test

2002 ◽  
Vol 35 (7) ◽  
pp. 783-788 ◽  
Author(s):  
A.M. Valença ◽  
A.E. Nardi ◽  
I. Nascimento ◽  
W.A. Zin ◽  
M. Versiani
Keyword(s):  
Carbon Dioxide ◽  
Panic Disorder ◽  
Challenge Test ◽  
Carbon Dioxide Challenge

[3H Paroxetine binding to platelets of patients with social phobia: Comparison to patients with panic disorder and healthy volunteers

1995 ◽  
Vol 37 (4) ◽  
pp. 224-228 ◽  
Author(s):  
Murray B. Stein ◽  
Suzanne M. Delaney ◽  
Mariette J. Chartier ◽  
Cara D.L. Kroft ◽  
Andrea L. Hazen
Keyword(s):  
Panic Disorder ◽  
Social Phobia ◽  
Healthy Volunteers ◽  
Paroxetine Binding

5-HT1A receptor binding in panic disorder; comparison with depressive disorder and healthy volunteers using PET and [11C]WAY-100635

NeuroImage ◽  
2000 ◽  
Vol 11 (5) ◽  
pp. S189 ◽  
Author(s):  
P. Sargent ◽  
J. Nash ◽  
S. Hood ◽  
E. Rabiner ◽  
C. Messa ◽  
...  
Keyword(s):  
Panic Disorder ◽  
Depressive Disorder ◽  
Healthy Volunteers ◽  
Receptor Binding ◽  
Way 100635

scholarly journals Experimental Affective Symptoms in Panic Disorder Patients

2005 ◽  
Vol 50 (3) ◽  
pp. 175-178 ◽  
Author(s):  
Thea Overbeek ◽  
Koen Schruers ◽  
Ine Docters van Leeuwen ◽  
Tineke Klaassen ◽  
Eric Griez
Keyword(s):  
Carbon Dioxide ◽  
Panic Disorder ◽  
Outcome Measure ◽  
Gas Mixture ◽  
Comorbid Depression ◽  
Major Depressive ◽  
Symptoms Of Depression ◽  
Affective Symptoms ◽  
Challenge Tests ◽  
Panic Symptoms

Objective: To date, carbon dioxide (CO2) challenge tests in panic disorder (PD) patients have focused on anxiety as the sole outcome measure. This study assesses a broader range of symptoms in patients with PD. Method: We administered a gas mixture of 35% CO2 and 65% oxygen (O2) to 25 patients with PD. Nine patients met the criteria for a comorbid major depressive disorder (MDD), and 16 did not. We assessed not only subjects' symptoms of anxiety but also their symptoms of depression and aggression. Results: Baseline ratings did not differ across the 2 subgroups. Postchallenge ratings were higher for PD and MDD patients on all the assessed affective symptoms, except for specific panic symptoms. Conclusion: These findings suggest that, in addition to anxiety, CO2 challenge induces depressive and aggressive symptoms, specifically in PD patients with comorbid depression.

scholarly journals Modulation by Muscarinic Antagonists of the Response to Carbon Dioxide Challenge in Panic Disorder

2001 ◽  
Vol 58 (2) ◽  
pp. 114 ◽  
Author(s):  
Marco Battaglia ◽  
Silvana Bertella ◽  
Anna Ogliari ◽  
Laura Bellodi ◽  
Enrico Smeraldi
Keyword(s):  
Carbon Dioxide ◽  
Panic Disorder ◽  
Muscarinic Antagonists ◽  
Carbon Dioxide Challenge

Phase I Safety Assessment of Intrathecal Neostigmine Methylsulfate in Humans 

1995 ◽  
Vol 82 (2) ◽  
pp. 331-343 ◽  
Author(s):  
David D. Hood ◽  
James C. Eisenach ◽  
Robin Tuttle
Keyword(s):  
Carbon Dioxide ◽  
Blood Pressure ◽  
Heart Rate ◽  
Side Effects ◽  
Healthy Volunteers ◽  
Nausea And Vomiting ◽  
Severe Nausea ◽  
End Tidal Carbon Dioxide ◽  
End Tidal ◽  
Ice Water

Background In dogs, sheep, and rats, spinal neostigmine produces analgesia alone and enhances analgesia from alpha 2-adrenergic agonists. This study assesses side effects and analgesia from intrathecal neostigmine in healthy volunteers. Methods After institutional review board approval and informed consent, 28 healthy volunteers were studied. The first 14 volunteers received neostigmine (50-750 micrograms) through a #19.5 spinal needle followed by insertion of a spinal catheter. The remaining 14 volunteers received neostigmine through a #25 or #27 spinal needle without a catheter. Safety measurements included blood pressure, heart rate, oxyhemoglobin saturation, end-tidal carbon dioxide, neurologic evaluation, and computer tests of vigilance and memory. Analgesia in response to ice water immersion was measured. Results Neostigmine (50 micrograms) through the #19.5 needle did not affect any measured variable. Neostigmine (150 micrograms) caused mild nausea, and 500-750 micrograms caused severe nausea and vomiting. Neostigmine (150-750 micrograms) produced subjective leg weakness, decreased deep tendon reflexes, and sedation. The 750-micrograms dose was associated with anxiety, increased blood pressure and heart rate, and decreased end-tidal carbon dioxide. Neostigmine (100-200 micrograms) in saline, injected through a #25 or #27 needle, caused protracted, severe nausea, and vomiting. This did not occur when dextrose was added to neostigmine. Neostigmine by either method of administration reduced visual analog pain scores to immersion of the foot in ice water. Conclusions The incidence and severity of these adverse events from intrathecal neostigmine appears to be affected by dose, method of administration, and baricity of solution. These effects in humans are consistent with studies in animals. Because no unexpected or dangerous side effects occurred, cautious examination of intrathecal neostigmine alone and in combination with other agents for analgesia is warranted.

P.4.a.019 Carbon dioxide-induced respiratory symptoms and experimental panic in healthy volunteers

2009 ◽  
Vol 19 ◽  
pp. S596
Author(s):  
A. Colasanti ◽  
K. Schruers ◽  
R. van Diest ◽  
G. Esquivel ◽  
E. den Boer ◽  
...  
Keyword(s):  
Carbon Dioxide ◽  
Healthy Volunteers ◽  
Respiratory Symptoms
Sign in / Sign up

Export Citation Format

Share Document